Brought to you by 
Genzyme,GelTex form 50-50 JV to market RenaGel; terminated
08 Sep 2004
Executive Summary
GelTex (polymer-based therapeutics) and Genzyme are forming a 50-50 joint venture RenaGel LLC to develop and commercialize GelTex's RenaGel, a treatment for chronic kidney failure patients.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- Joint Venture
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Genzyme,GelTex form 50-50 JV to market RenaGel; terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice